Literature DB >> 12456871

Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7.

Fabrizio Giordanetto1, Romano T Kroemer.   

Abstract

A theoretical model of human Janus kinase 2 (JAK2) comprising all seven Janus homology domains is presented. The model was generated by application of homology modelling approaches. The three-dimensional structure contains, starting from the N-terminus, FERM (4.1, ezrin, radixin, moesin), SH2 (Src homology region 2), tyrosine kinase-like, and tyrosine kinase domains. The predicted inter-domain orientation in JAK2 is discussed and the currently existing mutational data for Janus kinases are evaluated. Structural details of the SH2 and the FERM domains are presented. The predictions indicate that the SH2 domain is not fully functional. A number of hydrophobic amino acids of the FERM domain that are predicted to be involved in the constitutive association with the cytokine receptors are highlighted. The model gives new insights into the structure-function relationship of this important protein, and areas that could be investigated by mutation studies are highlighted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12456871     DOI: 10.1093/protein/15.9.727

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  35 in total

Review 1.  Mast cell homeostasis and the JAK-STAT pathway.

Authors:  J K Morales; Y T Falanga; A Depcrynski; J Fernando; J J Ryan
Journal:  Genes Immun       Date:  2010-06-10       Impact factor: 2.676

Review 2.  HiJAKing the epigenome in leukemia and lymphoma.

Authors:  Amanda C Drennan; Lixin Rui
Journal:  Leuk Lymphoma       Date:  2017-04-12

Review 3.  JAK2 inhibitors: what's the true therapeutic potential?

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Blood Rev       Date:  2010-11-20       Impact factor: 8.250

4.  Proteolysis of the barley receptor-like protein kinase RPG1 by a proteasome pathway is correlated with Rpg1-mediated stem rust resistance.

Authors:  Jayaveeramuthu Nirmala; Stephanie Dahl; Brian J Steffenson; C Gamini Kannangara; Diter von Wettstein; Xianming Chen; Andris Kleinhofs
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

Review 5.  Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.

Authors:  Jacqueline Sayyah; Peter P Sayeski
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

6.  Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.

Authors:  Wanlong Ma; Hagop Kantarjian; Xi Zhang; Chen-Hsiung Yeh; Zhong J Zhang; Srdan Verstovsek; Maher Albitar
Journal:  J Mol Diagn       Date:  2008-12-12       Impact factor: 5.568

7.  Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.

Authors:  John S Tokarski; Adriana Zupa-Fernandez; Jeffrey A Tredup; Kristen Pike; ChiehYing Chang; Dianlin Xie; Lihong Cheng; Donna Pedicord; Jodi Muckelbauer; Stephen R Johnson; Sophie Wu; Suzanne C Edavettal; Yang Hong; Mark R Witmer; Lisa L Elkin; Yuval Blat; William J Pitts; David S Weinstein; James R Burke
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

8.  JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.

Authors:  Wanlong Ma; Hagop Kantarjian; Xi Zhang; Xiuqiang Wang; Zhong Zhang; Chen-Hsiung Yeh; Susan O'Brien; Francis Giles; Jean Marie Bruey; Maher Albitar
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

9.  Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity.

Authors:  Megumi Funakoshi-Tago; Stéphane Pelletier; Hiroshi Moritake; Evan Parganas; James N Ihle
Journal:  Mol Cell Biol       Date:  2007-12-26       Impact factor: 4.272

10.  Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity.

Authors:  Lawrence S Argetsinger; Jean-Louis K Kouadio; Hanno Steen; Allan Stensballe; Ole N Jensen; Christin Carter-Su
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.